ZNTL

Zentalis Pharmaceuticals, Inc.

• TipRanks·06/18 21:17

  Zentalis Shareholders Back Directors, Auditors and Executive Pay

• TipRanks·06/15 11:42

  Zentalis assumed with an Outperform at Oppenheimer

• PUBT·06/01 21:00

  Zentalis grants 191,000 inducement stock options priced at $3.98 per share

• Reuters·06/01 21:00

  ZENTALIS PHARMACEUTICALS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

• Dow Jones·06/01 21:00

  Press Release: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

• TipRanks·05/27 20:42

  Zentalis Pharmaceuticals Expands Board, Appoints New Director

• Dow Jones·05/27 20:12

  *Zentalis Pharmaceuticals Names Shannon Campbell to Board

• PUBT·05/27 20:11

  Zentalis Pharma director Shannon Campbell files initial beneficial ownership statement

• PUBT·05/27 20:08

  Zentalis adds Shannon Campbell to board of directors

• Dow Jones·05/27 20:05

  Press Release: Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy

• Dow Jones·05/27 20:05

  Press Release: Zentalis Strengthens Commercial -2-

• TipRanks·05/26 17:48

  Zentalis Pharmaceuticals (ZNTL) Receives a Buy from H.C. Wainwright

• TipRanks·05/22 10:27

  Analyst Reiterates Buy on Zentalis as New MUIR Data Bolster Azenosertib Outlook; $10 Price Target Unchanged

• NASDAQ·05/22 10:01

  Zentalis To Present Part 1 Phase 1b MUIR Trial Results Of Azenosertib At ASCO 2026

• TipRanks·05/21 23:56

  Zentalis Highlights Promising Azenosertib Data in Ovarian Cancer